PT694042E - Inibidor do factor de crescimento de celulas endoteliais vasculares - Google Patents

Inibidor do factor de crescimento de celulas endoteliais vasculares

Info

Publication number
PT694042E
PT694042E PT94911403T PT94911403T PT694042E PT 694042 E PT694042 E PT 694042E PT 94911403 T PT94911403 T PT 94911403T PT 94911403 T PT94911403 T PT 94911403T PT 694042 E PT694042 E PT 694042E
Authority
PT
Portugal
Prior art keywords
growth factor
endothelial cells
vascular endothelial
vegf
soluble forms
Prior art date
Application number
PT94911403T
Other languages
English (en)
Inventor
Richard L Kendall
Kenneth A Thomas Jr
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PT694042E publication Critical patent/PT694042E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT94911403T 1993-03-25 1994-02-25 Inibidor do factor de crescimento de celulas endoteliais vasculares PT694042E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3876993A 1993-03-25 1993-03-25

Publications (1)

Publication Number Publication Date
PT694042E true PT694042E (pt) 2005-02-28

Family

ID=21901791

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94911403T PT694042E (pt) 1993-03-25 1994-02-25 Inibidor do factor de crescimento de celulas endoteliais vasculares

Country Status (12)

Country Link
US (5) US5712380A (pt)
EP (1) EP0694042B1 (pt)
JP (1) JP3734262B2 (pt)
AT (1) ATE281469T1 (pt)
AU (1) AU684498B2 (pt)
CA (1) CA2158745C (pt)
DE (1) DE69434115T2 (pt)
DK (1) DK0694042T3 (pt)
ES (1) ES2230542T3 (pt)
IL (1) IL109016A (pt)
PT (1) PT694042E (pt)
WO (1) WO1994021679A1 (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6710174B2 (en) * 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6828426B1 (en) 1996-07-15 2004-12-07 Chugai Seiyaku Kabushiki Kaisha VEGF-like factor
CA2266419A1 (en) * 1996-09-24 1998-04-02 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US6348333B1 (en) 1997-01-17 2002-02-19 Toa Gosei Co., Ltd. VEGF-binding KDR polypeptide
CA2328893A1 (en) * 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
US7317003B2 (en) * 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
CA2359461A1 (en) * 1999-01-15 2000-07-20 Medstar Research Institute Inhibiting development of microvessels within vascular walls
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7303746B2 (en) * 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
GB9928950D0 (en) * 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
JP2003525911A (ja) * 2000-03-08 2003-09-02 ニューロサーチ、アクティーゼルスカブ プロドラッグに対する内皮細胞の感受性を高める方法
AU2001288025A1 (en) 2000-09-05 2002-03-22 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
US20030181377A1 (en) * 2002-02-12 2003-09-25 Vanderbilt University Inhibition of VEGF receptor signaling reverses tumor resistance to radiotherapy
US20040101478A1 (en) * 2002-03-29 2004-05-27 Thomas Kenneth A In vivo methods of determining activity of receptor-type kinase inhibitors
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
CN101139393B (zh) 2002-09-12 2010-11-24 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
US7432341B2 (en) * 2002-10-24 2008-10-07 Valo Hsj, Limited Partnership Cytokine receptor modulators and method of modulating cytokine receptor activity
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2005113596A2 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
ATE548384T1 (de) * 2004-06-08 2012-03-15 Chengdu Kanghong Biotechnologies Co Ltd Ein die angiogenese inhibierendes chimäres protein und dessen verwendung
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
JP4944032B2 (ja) 2004-09-13 2012-05-30 ジェンザイム・コーポレーション 多量体構築物
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
PT1855707E (pt) * 2005-02-28 2012-05-25 Oncotherapy Science Inc Péptidos de epítopo derivados de receptor de factor de crescimento endotelial vascular 1 e vacinas contendo estes péptidos
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
EP1902145A4 (en) * 2005-07-13 2010-04-14 Beth Israel Hospital METHOD FOR DIAGNOSIS AND TREATMENT OF AN INFLAMMATORY REACTION
US9198981B2 (en) * 2006-02-01 2015-12-01 The University Of Kentucky Modulation of angiogenesis
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
EP2235529B1 (en) 2008-01-07 2016-12-14 Ortho-Clinical Diagnostics, Inc. Determination of sflt-1:angiogenic factor complex
WO2009149205A2 (en) * 2008-06-03 2009-12-10 Neurotech Usa, Inc. Cell lines that secrete soluble vegf receptors and uses thereof
WO2010091234A2 (en) 2009-02-06 2010-08-12 The General Hospital Corporation Methods of treating vascular lesions
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
WO2011028642A1 (en) 2009-09-04 2011-03-10 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation VEGF antagonist compositions and their use
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
JP6526570B2 (ja) 2013-01-11 2019-06-12 マサチューセッツ アイ アンド イヤー インファーマリー 炎症及び血管形成を減少させるｃｙｐ４５０脂質メタボライト
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10000741B2 (en) 2014-03-17 2018-06-19 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
KR101844596B1 (ko) 2014-03-18 2018-04-05 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질을 포함하는 안질환 치료용 조성물
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2955302A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
EA201791939A1 (ru) 2015-03-02 2018-01-31 Адверум Байотекнолоджиз, Инк. Композиции и способы интравитреальной доставки полинуклеотидов в колбочки сетчатки
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
US20190142975A1 (en) 2016-04-29 2019-05-16 Adverum Biotechnologies, Inc. Evasion of neutralizing antibodies by a recombinant adeno-associated virus
EP4427808A3 (en) 2016-06-16 2024-10-30 Adverum Biotechnologies, Inc. Compositions and methods for reducing ocular neovascularization
US11192925B2 (en) 2016-10-19 2021-12-07 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
SG11201907653QA (en) 2017-03-17 2019-09-27 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression
CN111741761B (zh) 2018-01-26 2023-04-18 加利福尼亚大学董事会 用于使用抗vegf剂治疗血管生成病症的方法和组合物
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CA3094391A1 (en) * 2018-03-22 2019-09-26 The Children's Medical Center Corporation Methods and compositions relating to lung repair
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
BR112023024375A2 (pt) 2021-05-28 2024-02-15 Shanghai Regenelead Therapies Co Ltd Vírus adeno-associado recombinante tendo capsídeo variante e sua aplicação
EP4426715A1 (en) * 2021-11-02 2024-09-11 Enumita AS Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0536350T3 (da) * 1991-02-22 2002-09-02 American Cyanamid Co Identifikation af et nyt humant receptor-tyrosinkinase-gen
ATE399181T1 (de) * 1992-10-28 2008-07-15 Genentech Inc Verwendung von antagonisten des zellwachstumsfaktors vegf
CN1701814A (zh) * 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1

Also Published As

Publication number Publication date
US5861484A (en) 1999-01-19
CA2158745C (en) 2007-06-19
IL109016A (en) 2005-07-25
US20030120038A1 (en) 2003-06-26
US20090247460A1 (en) 2009-10-01
DK0694042T3 (da) 2005-02-14
EP0694042A4 (en) 2001-05-02
US20070010442A1 (en) 2007-01-11
CA2158745A1 (en) 1994-09-29
DE69434115T2 (de) 2005-10-27
IL109016A0 (en) 1994-06-24
JPH08508161A (ja) 1996-09-03
EP0694042B1 (en) 2004-11-03
US7071159B2 (en) 2006-07-04
US8034772B2 (en) 2011-10-11
US5712380A (en) 1998-01-27
DE69434115D1 (de) 2004-12-09
ES2230542T3 (es) 2005-05-01
JP3734262B2 (ja) 2006-01-11
ATE281469T1 (de) 2004-11-15
AU684498B2 (en) 1997-12-18
AU6393494A (en) 1994-10-11
WO1994021679A1 (en) 1994-09-29
EP0694042A1 (en) 1996-01-31

Similar Documents

Publication Publication Date Title
PT694042E (pt) Inibidor do factor de crescimento de celulas endoteliais vasculares
DE69918946D1 (de) Rezeptoren für il-18
ATE350475T1 (de) Rezeptor an der oberfläche von aktivierten t- zellen:act4
EP2016953A3 (en) Vascular endothelial cell growth factor antagonists and uses thereof
DK0692025T3 (da) Gærceller, der er konstrueret således, at de producerer surrogater for proteiner i feromonsystemet, og anvendelser deraf
DE60203125D1 (de) Löslicher t zell rezeptor
PT1066380E (pt) Receptor de celula t soluvel
DE69934241D1 (de) Agonistische antikörper gegen tie2
EE9800353A (et) Pürasinoonidest trombiini inhibiitorid
WO1994015958A3 (en) Peptide inhibitors of cell adhesion
ES2057571T3 (es) Receptor de pdgf-alfa.
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
NO982715L (no) Endotel celle-proliferasjonsinhibitor og fremgangsmate for anvendelse
NZ514488A (en) Vascular endothelial cell growth factor variants and uses thereof
DE59801230D1 (de) Endothelin-rezeptorantagonisten zur bekämpfung von hyperlipidämie
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
AU2434400A (en) Method for the cellular high-throughput-detection of nuclear receptor ligand interactions
IT1263804B (it) Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista
DK0583352T3 (da) hGPIIB fragmenter og deres anvendelse i in vitro metoder til bestemmelse af in vivo thrombotiske tilstande
NO984233L (no) Cytokin kalt lerk-8
WO1996023883A3 (en) Modified ligands for receptor tyrosine kinases
ES2196360T3 (es) Ensayo de western blot que sirve para la identificacion de anticuerpos especificos del virus cmvh.
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)